Imnovid 4 mg hard capsules, JAMP Pomalidomide, Pomalidomide Adalvo 3 mg hard capsules, Imnovid 1 mg hard capsules, Imnovid 4 mg hard capsules, Pomalidomide Adalvo 1 mg hard capsules, Imnovid 2 mg hard capsules, JAMP Pomalidomide, Imnovid 1 mg hard capsules, JAMP Pomalidomide, Dexamethason 4 mg JENAPHARM®, Imnovid 3 mg hard capsules, Pomalidomide Adalvo 4 mg hard capsules, Pomalidomide Adalvo 2 mg hard capsules, Dexamethason 8 mg JENAPHARM®, Isatuximab, Isatuximab, JAMP Pomalidomide, Imnovid 3 mg hard capsul
ACT16482-01
Phase 2 small_molecule active
Quick answer
Imnovid 4 mg hard capsules, JAMP Pomalidomide, Pomalidomide Adalvo 3 mg hard capsules, Imnovid 1 mg hard capsules, Imnovid 4 mg hard capsules, Pomalidomide Adalvo 1 mg hard capsules, Imnovid 2 mg hard capsules, JAMP Pomalidomide, Imnovid 1 mg hard capsules, JAMP Pomalidomide, Dexamethason 4 mg JENAPHARM®, Imnovid 3 mg hard capsules, Pomalidomide Adalvo 4 mg hard capsules, Pomalidomide Adalvo 2 mg hard capsules, Dexamethason 8 mg JENAPHARM®, Isatuximab, Isatuximab, JAMP Pomalidomide, Imnovid 3 mg hard capsul for Cancer is a Phase 2 program (small_molecule) at Sanofi Pharma Bristol-Myers Squibb with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Sanofi Pharma Bristol-Myers Squibb
- Indication
- Cancer
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active